首页> 美国卫生研究院文献>Bulletin of the World Health Organization >Cost–effectiveness thresholds: pros and cons
【2h】

Cost–effectiveness thresholds: pros and cons

机译:成本效益阈值:利弊

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost–effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost–effectiveness thresholds allow cost–effectiveness ratios that represent good or very good value for money to be identified. In 2001, the World Health Organization’s Commission on Macroeconomics in Health suggested cost–effectiveness thresholds based on multiples of a country’s per-capita gross domestic product (GDP). In some contexts, in choosing which health interventions to fund and which not to fund, these thresholds have been used as decision rules. However, experience with the use of such GDP-based thresholds in decision-making processes at country level shows them to lack country specificity and this – in addition to uncertainty in the modelled cost–effectiveness ratios – can lead to the wrong decision on how to spend health-care resources. Cost–effectiveness information should be used alongside other considerations – e.g. budget impact and feasibility considerations – in a transparent decision-making process, rather than in isolation based on a single threshold value. Although cost–effectiveness ratios are undoubtedly informative in assessing value for money, countries should be encouraged to develop a context-specific process for decision-making that is supported by legislation, has stakeholder buy-in, for example the involvement of civil society organizations and patient groups, and is transparent, consistent and fair.
机译:成本效益分析用于比较替代政策选择的成本和结果。每个由此产生的成本效益比代表着每增加一单位资源所获得的额外健康水平。成本效益阈值可以确定成本效益比率,该比率代表物有所值或非常物有所值。 2001年,世界卫生组织卫生宏观经济学委员会提出了基于一个国家人均国内生产总值(GDP)倍数的成本效益阈值。在某些情况下,在选择资助哪些健康干预措施和不资助哪些健康干预措施时,这些阈值已被用作决策规则。但是,在国家一级的决策过程中使用此类基于GDP的阈值的经验表明,它们缺乏国家的针对性,这不仅会导致成本效益比模型的不确定性,还会导致如何做出错误的决定。花费医疗资源。成本效益信息应与其他注意事项一起使用,例如预算影响和可行性考虑–在透明的决策过程中,而不是孤立地基于单个阈值。尽管成本效益比无疑在评估物有所值方面提供了信息,但应鼓励各国制定一种因地制宜的决策程序,并得到立法的支持,有利益相关者的支持,例如民间社会组织和政府的参与。病人群体,并且是透明,一致和公平的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号